https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19267
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir can decrease the P-gp and increase the plasma concentration of Digoxin.
–
–
–
Possible increase of adverse effects.
Use this combination with caution.
Therapeutic concentration monitoring of is recommended before initiating and during glecaprevir/pibrentasvir therapy.
Product monograph suggests to decrease the dose by approximately 50% or modify the dosing frequency and continue monitoring.
–
Adverse effects of digoxin: Gastrointestinal effects (abdominal discomfort, nausea/vomiting, diarrhea, anorexia, dyspepsia), central nervous system effects, vision disorders, fatigue, headache, bradycardia and rhythm disorders.
Digoxinemia
Reference number |
---|
# patients |
HCV |
Dose |
Frequency |
Cmax |
AUC |
3373 |
---|
12 |
- |
400/120 mg |
QD |
3373 |
---|
12 |
- |
0.5 mg |
x 1 |
+ 72% |
+ 48% |
Ref #3373 : No significant changes in glecaprevir or pibrentasvir concentrations.